Base edited "universal" donor CAR T-cell strategies for acute myeloid leukaemia [0.03%]
用于急性髓系白血病的基本编辑的“通用”供者CAR-T细胞策略
Renuka Kadirkamanathan,Christos Georgiadis,Arnold Kloos et al.
Renuka Kadirkamanathan et al.
Acute myeloid leukaemia (AML) is often aggressive and life-threatening with limited curative options. Immunotherapies including chimeric antigen receptor (CAR) T-cell approaches are under investigation, but high levels of disease heterogene...
Regulation of metabolic adaptation and leukemia progression by MUSASHI2-DEPTOR-KIF11 axis [0.03%]
MUSASHI2-DEPTOR-KIF11轴调控代谢适应和白血病进展
Tania Setiawan,Jabir Aliyu Muhammad,Nadya Marcellina et al.
Tania Setiawan et al.
Amino acid homeostasis is critical for leukemic cell survival, with the mTOR pathway playing a central role in sensing and responding to nutrient availability. DEPTOR, a component and negative regulator of mTOR complexes, has been extensive...
Christophe Badie,Robert Peter Gale
Christophe Badie
Refining PET-based response in extramedullary multiple myeloma using total lesion glycolysis [0.03%]
基于总病变糖酵解的髓外多发性骨髓瘤阴性预测值PET阳性标准的优化研究
Saurabh Zanwar,Gokce Belge Bilgin,Stephen M Broski et al.
Saurabh Zanwar et al.
Positron Emission Tomography (PET)-based assessments are an integral part of response assessment in patients with multiple myeloma (MM) with extramedullary disease (EMD), yet their utility in EMD remains to be systematically studied. We ret...
Misclassification of TP53 germline variants: implications for survival analysis in AML transplant studies [0.03%]
TP53胚系变异的误分类对AML移植研究生存分析的影响
Léa Rodriguez,François Delhommeau,Thierry Soussi
Léa Rodriguez
Correction: Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML [0.03%]
纠正：纵向单细胞分析揭示了儿科急性髓系白血病的耐药干细胞和肥大细胞及其潜在治疗方法
Denis Ohlstrom,Mojtaba Bakhtiari,Hope Mumme et al.
Denis Ohlstrom et al.
Published Erratum
Leukemia. 2025 Sep 19. DOI:10.1038/s41375-025-02773-6 2025
The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma [0.03%]
嵌合抗原受体T细胞治疗重塑了骨髓瘤患者体内固有的T细胞图谱并可预测治疗效果
Julia Frede,Julia C Poller,Kayleen Shi et al.
Julia Frede et al.
While most patients initially respond to CAR-T cell treatment, responses often are not durable and subsequent lines of immunotherapy show diminishing success. In this study, we investigated the co-evolutionary dynamics between CAR-T cells a...
Maria Eleftheriou,James Russell,Konstantinos Tzelepis
Maria Eleftheriou
RNA modifications, collectively termed the epitranscriptome, constitute a dynamic layer of post-transcriptional regulation that governs RNA splicing, stability, localization, translation, and decay. In the hematopoietic system, these chemic...
Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study [0.03%]
t(14;19)阳性慢性淋巴细胞白血病患者的临床和转录组特征分析（ERIC研究）
Andrea Visentin,Enrico Gaffo,Moritz Fürstenau et al.
Andrea Visentin et al.
In chronic lymphocytic leukemia (CLL), the role of complex karyotype (CK) for prognostic stratification remains a topic of debate, and the impact of specific cytogenetic abnormalities is still unclear. This study aims to investigate the cli...
Clonal evolution and apoptosis resistance in myelodysplastic neoplasms and acute myeloid leukemia under treatment: insights from integrative longitudinal profiling [0.03%]
整合纵向分析在治疗过程中骨髓增生异常肿瘤和急性髓系白血病的克隆进化及凋亡抵抗提供的见解
Paolo Mazzeo,Sarah Mae Penir,Evgenii Shumilov et al.
Paolo Mazzeo et al.
Treatment of high-risk Myelodysplastic Neoplasms (hr-MDS) and (secondary) Acute Myeloid Leukemia (AML) remains a clinical challenge. The combination of azacitidine and venetoclax (aza/ven) may improve treatment outcomes, but still fails in ...